Mometasone Furoate/Formoterol Shows Similar Efficacy to Fluticasone Propionate/Salmeterol in Severe Asthma: Presented at AAAAI
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Mometasone Furoate/Formoterol Shows Similar Efficacy to Fluticasone Propionate/Salmeterol in Severe Asthma: Presented at AAAAI

By Em Brown

WASHINGTON, DC -- March 20, 2009 -- Mometasone furoate/formoterol (MF/F) via a single metered-dose inhaler (MDI) is a safe, effective alternative to fluticasone propionate/salmeterol (FP/S) for the treatment of moderate to severe persistent asthma, investigators stated here on March 17 at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

Jorge F. Maspero, MD, Fundacion CIDEA, Allergy and Respiratory Research Institute, Buenos Aires, Argentina, presented the results of a randomised study assessing the long-term safety of MF/F in patients with moderate to severe asthma previously treated with medium- to high-dose inhaled corticosteroids.

A total of 404 patients, aged 12 years and older, were randomised to twice daily doses of MF/F 200/10 mcg (n = 141); MF/F 250/50 mcg (n = 130); FP/S 400/10 mcg (n = 68); or FP/S 500/50 mcg (n = 65), for 1 year. The primary endpoint was the percentage of patients reporting adverse events.

All regimens were well tolerated, with similar rates of adverse events. The most common treatment-related adverse events in the MF/F group were dysphonia (5% medium-dose group, 3.1% high-dose group) and headache (4.3% medium-dose group, 3.1% high-dose group).

In patients receiving FP/S, headache occurred in 5.9% of the medium-dose group and in 1.5% of those on the higher dose. Arthralgia occurred in 4.4% of the medium-dose group and 1.5% of high-dose group.

Oral candidiasis was uncommon, occurring in 1.1% of mometasone-treated patients and in 2.2% of fluticasone-treated patients.

"Mometasone furoate/formoterol was well tolerated over 1 year at medium and high doses, with a safety profile similar to fluticasone/salmeterol and no unusual or unexpected adverse events," Dr. Maspero concluded.

Funding for this study was provided by a grant from Schering-Plough.

[Presentation title: Long-term Safety and Tolerability of Two Doses of Mometasone Furoate/Formoterol (MF/F) Combination, Administered Via a Metered-dose Inhaler, for the Treatment of Moderate-to-Severe Persistent Asthma. Abstract 606]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities